# A Study of GC101 TIL in Advanced Breast Cancer (10hospital)

> **NCT05142475** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer
- Treatment Side Effects
- Advanced Breast Cancer
- Effects of Immunotherapy

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes (TIL)

## Key facts

- **NCT ID:** NCT05142475
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-19
- **Primary completion:** 2026-12-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142475, "A Study of GC101 TIL in Advanced Breast Cancer (10hospital)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05142475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*